307 related articles for article (PubMed ID: 22707521)
1. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience.
Stressmann FA; Rogers GB; van der Gast CJ; Marsh P; Vermeer LS; Carroll MP; Hoffman L; Daniels TW; Patel N; Forbes B; Bruce KD
Thorax; 2012 Oct; 67(10):867-73. PubMed ID: 22707521
[TBL] [Abstract][Full Text] [Related]
2. Decade-long bacterial community dynamics in cystic fibrosis airways.
Zhao J; Schloss PD; Kalikin LM; Carmody LA; Foster BK; Petrosino JF; Cavalcoli JD; VanDevanter DR; Murray S; Li JZ; Young VB; LiPuma JJ
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5809-14. PubMed ID: 22451929
[TBL] [Abstract][Full Text] [Related]
3. The airway microbiome in cystic fibrosis and implications for treatment.
Zemanick ET; Sagel SD; Harris JK
Curr Opin Pediatr; 2011 Jun; 23(3):319-24. PubMed ID: 21494150
[TBL] [Abstract][Full Text] [Related]
4. Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis.
Daniels TW; Rogers GB; Stressmann FA; van der Gast CJ; Bruce KD; Jones GR; Connett GJ; Legg JP; Carroll MP
J Cyst Fibros; 2013 Jan; 12(1):22-8. PubMed ID: 22717533
[TBL] [Abstract][Full Text] [Related]
5. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations.
Fodor AA; Klem ER; Gilpin DF; Elborn JS; Boucher RC; Tunney MM; Wolfgang MC
PLoS One; 2012; 7(9):e45001. PubMed ID: 23049765
[TBL] [Abstract][Full Text] [Related]
6. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition.
Rogers GB; van der Gast CJ; Cuthbertson L; Thomson SK; Bruce KD; Martin ML; Serisier DJ
Thorax; 2013 Aug; 68(8):731-7. PubMed ID: 23564400
[TBL] [Abstract][Full Text] [Related]
7. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis.
Tunney MM; Klem ER; Fodor AA; Gilpin DF; Moriarty TF; McGrath SJ; Muhlebach MS; Boucher RC; Cardwell C; Doering G; Elborn JS; Wolfgang MC
Thorax; 2011 Jul; 66(7):579-84. PubMed ID: 21270069
[TBL] [Abstract][Full Text] [Related]
8. High individuality of respiratory bacterial communities in a large cohort of adult cystic fibrosis patients under continuous antibiotic treatment.
Kramer R; Sauer-Heilborn A; Welte T; Jauregui R; Brettar I; Guzman CA; Höfle MG
PLoS One; 2015; 10(2):e0117436. PubMed ID: 25671713
[TBL] [Abstract][Full Text] [Related]
9. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
[TBL] [Abstract][Full Text] [Related]
10. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis.
Rogers GB; Carroll MP; Serisier DJ; Hockey PM; Jones G; Kehagia V; Connett GJ; Bruce KD
J Clin Microbiol; 2006 Jul; 44(7):2601-4. PubMed ID: 16825392
[TBL] [Abstract][Full Text] [Related]
11. The metabolic footprint of the airway bacterial community in cystic fibrosis.
Narayanamurthy V; Sweetnam JM; Denner DR; Chen LW; Naureckas ET; Laxman B; White SR
Microbiome; 2017 Jun; 5(1):67. PubMed ID: 28666467
[TBL] [Abstract][Full Text] [Related]
12. Effects of Propidium Monoazide (PMA) Treatment on Mycobiome and Bacteriome Analysis of Cystic Fibrosis Airways during Exacerbation.
Nguyen LD; Deschaght P; Merlin S; Loywick A; Audebert C; Van Daele S; Viscogliosi E; Vaneechoutte M; Delhaes L
PLoS One; 2016; 11(12):e0168860. PubMed ID: 28030619
[TBL] [Abstract][Full Text] [Related]
13. Bacterial activity in cystic fibrosis lung infections.
Rogers GB; Carroll MP; Serisier DJ; Hockey PM; Kehagia V; Jones GR; Bruce KD
Respir Res; 2005 Jun; 6(1):49. PubMed ID: 15929792
[TBL] [Abstract][Full Text] [Related]
14. The genus Prevotella in cystic fibrosis airways.
Field TR; Sibley CD; Parkins MD; Rabin HR; Surette MG
Anaerobe; 2010 Aug; 16(4):337-44. PubMed ID: 20412865
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of diversity within the genus Pseudomonas in the lungs of cystic fibrosis patients.
Spasenovski T; Carroll MP; Payne MS; Bruce KD
Diagn Microbiol Infect Dis; 2009 Mar; 63(3):261-7. PubMed ID: 19216939
[TBL] [Abstract][Full Text] [Related]
17. Culture enriched molecular profiling of the cystic fibrosis airway microbiome.
Sibley CD; Grinwis ME; Field TR; Eshaghurshan CS; Faria MM; Dowd SE; Parkins MD; Rabin HR; Surette MG
PLoS One; 2011; 6(7):e22702. PubMed ID: 21829484
[TBL] [Abstract][Full Text] [Related]
18. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.
Tunney MM; Field TR; Moriarty TF; Patrick S; Doering G; Muhlebach MS; Wolfgang MC; Boucher R; Gilpin DF; McDowell A; Elborn JS
Am J Respir Crit Care Med; 2008 May; 177(9):995-1001. PubMed ID: 18263800
[TBL] [Abstract][Full Text] [Related]
19. Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period.
Stokell JR; Gharaibeh RZ; Hamp TJ; Zapata MJ; Fodor AA; Steck TR
J Clin Microbiol; 2015 Jan; 53(1):237-47. PubMed ID: 25392361
[TBL] [Abstract][Full Text] [Related]
20. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
Emerson J; McNamara S; Buccat AM; Worrell K; Burns JL
Pediatr Pulmonol; 2010 Apr; 45(4):363-70. PubMed ID: 20232473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
